SCHEMBL5526532

SCHEMBL5526532

O=C(O)CC(NC(=O)N1CCN(C(=O)c2ccco2)CC1)C1CCCCC1.[LiH]

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 8/20 0.52
KMT2A Q03164 1/20 0.51
LMNA P02545 1/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 2/20 0.48
USP2 O75604 1/20 0.48
GAA P10253 1/20 0.48
NPBWR1 P48145 1/20 0.48
MCHR1 Q99705 1/20 0.48
CYP2D6 P10635 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7046490 0.99 PKM (0.54) PKMSMN1; SMN2KDM4EALDH1A1KMT2A
SCHEMBL5530718 0.82 DPP7 (0.55) PKMSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL7046489 0.78 ALDH1A1 (0.56) PKMSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5521695 0.78 HTT (0.47) PKMKDM4EALDH1A1CYP2C19TSHR
SCHEMBL5523635 0.76 PKM (0.48) PKMSMN1; SMN2KDM4EALDH1A1KMT2A
Lithium Ion SCHEMBL5526530 0.74 ALDH1A1 (0.54) PKMSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5530343 0.73 POLB (0.50) PKMSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL5520636 0.72 L3MBTL1 (0.51) SMN1; SMN2KDM4EALDH1A1KMT2AGAA
SCHEMBL5530337 0.72 CTSS (0.56) SMN1; SMN2KDM4EALDH1A1CYP2C19NPSR1
SCHEMBL7598523 0.71 DPP7 (0.55) PKMSMN1; SMN2KDM4EALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed
EP-1178958-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-02-13 EP disclosed
WO-2000055125-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 PKM 3143/4885SMN1; SMN2 3462/4885KDM4E 2428/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 PKM 3143/4885SMN1; SMN2 3462/4885KDM4E 2428/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 PKM 3143/4885SMN1; SMN2 3462/4885KDM4E 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.